Charleston Iluvien Injection: How It Works, Results and What to Expect

A Charleston Iluvien injection generally refers to treatment with ILUVIEN, a tiny sustained-release implant placed inside the eye to manage chronic diabetic macular edema in carefully selected patients. It can reduce retinal swelling for some people, but requires ongoing eye-pressure and retina monitoring because steroid-related side effects may occur.

Overview: What Is a Charleston Iluvien Injection?

A Charleston Iluvien injection usually means an ILUVIEN treatment provided by an ophthalmology service in Charleston or another local setting. ILUVIEN is not a standard liquid injection that disappears quickly. It is a very small implant that is placed into the vitreous, the gel-like space inside the eye, where it gradually releases fluocinolone acetonide, a corticosteroid medicine.

The implant is designed to reduce inflammation that contributes to swelling in the macula, the central part of the retina responsible for detailed vision. It is used for selected adults with diabetic macular edema (DME), an eye complication of diabetes that can blur central vision. DME is a form of diabetic retinopathy and needs regular retinal assessment even when vision seems stable.

ILUVIEN is a longer-term management option rather than a cure for diabetes or all retinal disease. Whether it is appropriate depends on the cause of macular swelling, prior treatments, eye-pressure history, lens status and the ability to attend follow-up visits.

How ILUVIEN Works and What It Is Approved For

ILUVIEN contains fluocinolone acetonide, a corticosteroid that helps suppress inflammatory processes involved in diabetic macular edema. After placement, the implant releases a very low amount of medicine over an extended period. By reducing inflammation, it may help decrease retinal thickening and support improvement or stabilization of vision in appropriate patients.

In the United States, ILUVIEN is approved for diabetic macular edema in adults who have previously been treated with corticosteroids and did not have a clinically significant rise in intraocular pressure. This prior-response requirement is important because corticosteroids can raise pressure inside the eye in some people, potentially damaging the optic nerve if not recognized and treated.

Approval and availability can differ between countries. An ophthalmologist should confirm the locally approved indication and discuss alternatives, including laser treatment, anti-VEGF injections or other steroid approaches. Management may also involve diabetic retinopathy treatment tailored to the person’s retinal findings.

Who May Be a Candidate for ILUVIEN?

Potential candidates are adults with chronic or persistent diabetic macular edema whose ophthalmologist believes a sustained-release steroid implant may offer benefit. Many have previously received other therapies, such as anti-VEGF eye injections, focal or grid laser treatment, or shorter-acting corticosteroid treatments. The decision is individualized; having DME alone does not automatically mean ILUVIEN is the best option.

Before recommending treatment, the retina specialist typically reviews visual symptoms, retinal scans such as optical coherence tomography (OCT), prior treatment response, eye pressure measurements and the health of the optic nerve. Diabetes management, blood pressure and kidney health may also be considered because these can influence diabetic eye disease.

ILUVIEN may not be suitable for an eye with an active or suspected eye infection, certain forms of glaucoma, or a known allergy to product components. People with a history of steroid-related eye-pressure elevation need especially careful evaluation. Pregnancy, breastfeeding and other medical circumstances should be discussed with the treating clinician.

• Persistent or recurrent DME despite previous management may prompt discussion of an implant.
• A previous steroid trial without significant pressure elevation is generally relevant to candidacy in the United States.
• Reliable follow-up is essential because pressure changes and cataract development can occur gradually.

What Happens During the Procedure?

ILUVIEN placement is generally an outpatient procedure performed by a retina specialist or ophthalmologist. The eye is checked before treatment, and dilating drops may be used depending on the clinic’s process. The skin around the eye and the eye surface are cleaned with an antiseptic to lower the risk of infection.

Numbing drops and, in some cases, additional local anesthetic are used to make the procedure more comfortable. The clinician asks the person to look in a specific direction, then uses the single-use applicator to place the tiny implant through the white part of the eye. The procedure itself is brief, although preparation and post-procedure checks take longer.

Afterward, the eye team may check vision and eye pressure and provide written instructions. People should arrange transport home because the eye may be blurry or dilated. They should use only the drops or medicines advised by their clinician and should not rub or press on the treated eye.

Results, Benefits and Recovery Timeline

The intended benefit of ILUVIEN is improved control of diabetic macular edema over time, which may lead to less retinal swelling and improved or stabilized central vision. Results vary substantially. Vision changes depend not only on fluid in the retina but also on the degree of existing macular damage, the duration of edema, diabetes control and other eye conditions.

Some people notice temporary irritation, a foreign-body sensation, floaters or blurred vision on the day of treatment. These effects commonly settle within a short period, but recovery is not identical for everyone. The retina does not always respond immediately; follow-up OCT imaging helps the clinician judge changes in swelling over the following weeks and months.

Most people do not need bed rest after an intravitreal procedure. They can usually return to quiet daily activities the next day, provided vision is adequate and their clinician has not given different instructions. It is sensible to avoid rubbing the eye and to postpone swimming, hot tubs and strenuous activity for the period recommended by the eye team.

Regular appointments remain necessary even if vision improves. The implant can continue releasing medicine over a prolonged period, and the specialist monitors vision, the retina, eye pressure and the lens. Diabetes-related eye care may also include comprehensive eye examinations at intervals advised by the clinician.

Risks and Side Effects to Understand

All intravitreal procedures have risks, although serious complications are uncommon. Possible short-term effects include mild discomfort, redness, tearing, floaters, temporary blurred vision and a small area of bleeding on the white of the eye. These should be assessed if they are severe, worsening or not improving as expected.

Because ILUVIEN is a corticosteroid implant, increased intraocular pressure is a key concern. Pressure may rise after treatment and may require pressure-lowering drops, laser treatment or surgery in some cases. Cataract development or progression is also common in eyes with a natural lens after intraocular steroid exposure and may eventually require cataract surgery.

Less common but urgent complications can include infection inside the eye (endophthalmitis), retinal tear or detachment, bleeding inside the eye, inflammation and significant vision loss. The treating ophthalmologist explains individual risks, alternatives and warning symptoms before consent. A person should not delay contacting their eye clinic if they are worried after treatment.

How Much Does an ILUVIEN Injection Cost?

The cost of an ILUVIEN injection cannot be stated as one reliable figure because it varies between countries, hospitals and clinics. It may include the implant, the procedure, retinal imaging, consultation visits, follow-up monitoring and any treatment needed for side effects. Insurance coverage, prior authorization rules and public-health eligibility can also affect out-of-pocket costs.

Before treatment, patients can ask the clinic’s financial or patient-services team for an itemized estimate and clarification of what is included. They may also ask their insurer whether the treatment is covered for their diagnosis and whether documentation of previous therapies is required.

Cost should be considered alongside clinical suitability and monitoring needs. A lower immediate cost does not necessarily reflect the total care required over time, and a retina specialist can help compare appropriate treatment options based on the individual eye condition.

When to Seek Medical Care

After an ILUVIEN procedure, patients should contact their ophthalmologist promptly for increasing eye pain, worsening redness, increasing light sensitivity, a sudden reduction in vision, new flashes of light, a rapidly increasing number of floaters or a curtain-like shadow in the field of vision. These symptoms may indicate a complication that needs urgent assessment.

Anyone with diabetes should arrange an eye examination promptly if they develop new blurred vision, distorted straight lines, dark spots in central vision or difficulty reading that does not clear. Diabetic retinopathy and macular edema can sometimes progress with few early symptoms, so scheduled dilated retinal examinations remain important.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals evaluate and treat diabetic eye conditions for international patients. A retina specialist can explain whether an intravitreal implant, another injection treatment, laser therapy or observation is most appropriate for the individual situation.

Frequently asked questions

How many days should I rest after an eye injection?

Most people do not need strict bed rest after an intravitreal eye injection or implant procedure. Quiet activities can often be resumed the same day or the next day, but driving should be avoided until vision is clear and the person feels safe. The treating ophthalmologist may recommend temporarily avoiding swimming, hot tubs, eye rubbing and strenuous exercise.

How much does an ILUVIEN injection cost?

ILUVIEN costs vary by country, clinic, insurance plan, medication coverage and the follow-up care required. The overall expense may include the implant, procedure, retinal imaging and monitoring visits. A clinic and insurance provider can give the most accurate estimate for a specific patient.

What is the success rate of intravitreal injections?

There is no single success rate for intravitreal injections because outcomes depend on the disease being treated, the medicine used, the severity of retinal damage and prior response to treatment. For diabetic macular edema, treatment aims to reduce retinal swelling and preserve or improve vision where possible. Retina specialists assess response using vision testing and retinal imaging over time rather than relying on one universal percentage.

What is ILUVIEN approved for?

In the United States, ILUVIEN is approved for diabetic macular edema in adults who have previously been treated with corticosteroids and did not have a clinically significant increase in eye pressure. Approved uses may differ in other countries. An ophthalmologist can confirm the indication that applies in the patient’s location and clinical situation.

Is ILUVIEN the same as an anti-VEGF injection?

No. ILUVIEN is a sustained-release corticosteroid implant containing fluocinolone acetonide, while anti-VEGF injections use medicines that block vascular endothelial growth factor. Both may be used in diabetic macular edema, but they work differently and have different benefits, risks and treatment schedules.

Can ILUVIEN improve vision permanently?

ILUVIEN may reduce macular swelling and help improve or stabilize vision in some suitable patients, but it does not reverse all retinal damage or cure diabetes. The durability of benefit varies, and vision can be affected by ongoing diabetic retinopathy, cataract, glaucoma or other eye disease. Continued monitoring and diabetes care remain important.

References

• U.S. Food and Drug Administration
• American Academy of Ophthalmology
• National Eye Institute
• American Diabetes Association
• European Society of Retina Specialists

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.